Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure

Prisco, Domenico;Barcellona, Doris;
2021-01-01

Abstract

Trial of Rivaroxaban in AntiPhospholipid Syndrome was a prospective randomized, open-label, noninferiority study conducted in 14 centers in Italy. Rivaroxaban was compared with warfarin for the prevention of thromboembolic events, major bleeding, and vascular death in high-risk, triple-positive patients with antiphospholipid syndrome.
2021
2020
Inglese
19
2
531
535
5
WOS:000593984400001
2-s2.0-85096875107
33128325
Esperti anonimi
internazionale
scientifica
no
Pengo, Vittorio; Hoxha, Ariela; Andreoli, Laura; Tincani, Angela; Silvestri, Elena; Prisco, Domenico; Fierro, Tiziana; Gresele, Paolo; Cafolla, Arturo; De Micheli, Valeria; Ghirarduzzi, Angelo; Tosetto, Alberto; Falanga, Anna; Martinelli, Ida; Testa, Sophie; Barcellona, Doris; Gerosa, Maria; Denas, Gentian
1.1 Articolo in rivista
info:eu-repo/semantics/article
1 Contributo su Rivista::1.1 Articolo in rivista
262
18
reserved
File in questo prodotto:
File Dimensione Formato  
2020 JTH (1).pdf

Solo gestori archivio

Tipologia: versione post-print
Dimensione 5.92 MB
Formato Adobe PDF
  Visualizza/Apri   Richiedi una copia
5.92 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Questionario e social

Condividi su:
Impostazioni cookie